贝伐单抗联合节拍化疗在晚期非小细胞肺癌治疗中的临床效果观察

Observation on clinical effect of bevacizumab combined with metronomic chemotherapy in the treatment of advanced non-smallcell lung cancer

目的分析贝伐单抗联合节拍化疗在晚期非小细胞肺癌治疗中的临床效果。方法 120例晚期非小细胞肺癌患者作为研究对象,依据双盲法分为对照组及观察组,各60例。对照组采用节拍化疗,观察组采用贝伐单抗联合节拍化疗。比较两组患者的治疗效果,治疗前后的临床症状评分及治疗后的生活质量评分。结果观察组疾病控制率91.67%高于对照组的60.00%,差异具有统计学意义(P<0.05)。治疗后,观察组患者的恶心呕吐、咳嗽、气促、疲乏、胸痛评分分别为(30.21±2.48)、(31.26±1.54)、(32.59±1.54)、(29.26±3.26)、(31.59±2.48)分,低于对照组的(43.02±1.58)、(40.23±2.19)、(41.21±0.63)、(38.55±4.29)、(38.21±2.24)分,差异具有统计学意义(P<0.05)。观察组的躯体评分、心理评分、社会评分、物质评分、生活质量总评分分别为(21.69±2.58)、(20.36±3.25)、(22.69±2.11)、(21.58±3.09)、(86.32±3.87)分,显著高于对照组的(15.26±2.55)、(15.11±1.47)、(14.23±3.28)、(15.69±2.11)、(60.29±3.76)分,差异具有统计学意义(P<0.05)。结论贝伐单抗联合节拍化疗治疗晚期非小细胞肺癌患者,可缓解临床症状,改善生活质量,保证整体临床疗效的提升,值得推荐。

Objective To analyze the clinical effect of bevacizumab combined with metronomic chemotherapy in the treatment of advanced non-smallcell lung cancer.Methods A total of 120 patients with advanced non-smallcell lung cancer as the research subjects were divided into the control group and the observation group according to the double-blind method,with 60 cases in each group.The control group was treated with metronomic chemotherapy,and the observation group was treated with bevacizumab in combination with metronomic chemotherapy.The therapeutic effects,clinical symptom scores and quality of life scores before and after treatment were compared between the two groups.Results The disease control rate 91.67% of the observation group was higher than 60.00% of the control group,and the difference was statistically significant(P<0.05).After treatment,the scores of nausea and vomiting,cough,shortness of breath,fatigue,and chest pain of the observation group were(30.21±2.48),(31.26±1.54),(32.59±1.54),(29.26±3.26),and(31.59±2.48) points,which were lower than(43.02±1.58),(40.23±2.19),(41.21±0.63),(38.55±4.29),and(38.21±2.24) points of the control group,and the difference was statistically significant(P<0.05).The somatic score,psychological score,social score,material score,and total quality of life score of the observation group were(21.69±2.58),(20.36±3.25),(22.69±2.11),(21.58±3.09),and(86.32±3.87) points,which were significantly higher than(15.26±2.55),(15.11±1.47),(14.23±3.28),(15.69±2.11),and(60.29±3.76) points of the control group,and the difference was statistically significant(P<0.05).Conclusion Bevacizumab in combination with metronomic chemotherapy for the treatment of advanced non-smallcell lung cancer can relieve clinical symptoms,improve the quality of life,and ensure the improvement of overall clinical efficacy.It is worth recommending.